162 related articles for article (PubMed ID: 38355839)
1. Stratifying ICIs-responsive tumor microenvironment in HCC: from parsing out immune-hypoxic crosstalk to clinically applicable MRI-radiomics models.
Song LN; Wang B; Cai JL; Zhang PL; Chen SP; Zhou ZJ; Dai Z
Br J Cancer; 2024 May; 130(8):1356-1364. PubMed ID: 38355839
[TBL] [Abstract][Full Text] [Related]
2. A novel stemness-hypoxia-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma.
Zhang G; Zhang K; Zhao Y; Yang Q; Lv X
BMC Cancer; 2022 Oct; 22(1):1103. PubMed ID: 36307751
[TBL] [Abstract][Full Text] [Related]
3. MRI radiomics to monitor therapeutic outcome of sorafenib plus IHA transcatheter NK cell combination therapy in hepatocellular carcinoma.
Yu G; Zhang Z; Eresen A; Hou Q; Garcia EE; Yu Z; Abi-Jaoudeh N; Yaghmai V; Zhang Z
J Transl Med; 2024 Jan; 22(1):76. PubMed ID: 38243292
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial targeting of immune checkpoints and epigenetic regulators for hepatocellular carcinoma therapy.
Akce M; El-Rayes BF; Wajapeyee N
Oncogene; 2023 Mar; 42(14):1051-1057. PubMed ID: 36854723
[TBL] [Abstract][Full Text] [Related]
5. DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma.
Chen Y; Wang X; Deng X; Zhang Y; Liao R; Li Y; Yang H; Chen K
Front Immunol; 2021; 12():676922. PubMed ID: 34335575
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitor resistance in hepatocellular carcinoma.
Wang Z; Wang Y; Gao P; Ding J
Cancer Lett; 2023 Feb; 555():216038. PubMed ID: 36529238
[TBL] [Abstract][Full Text] [Related]
7. Development of a machine learning-based radiomics signature for estimating breast cancer TME phenotypes and predicting anti-PD-1/PD-L1 immunotherapy response.
Han X; Guo Y; Ye H; Chen Z; Hu Q; Wei X; Liu Z; Liang C
Breast Cancer Res; 2024 Jan; 26(1):18. PubMed ID: 38287356
[TBL] [Abstract][Full Text] [Related]
8. A radiomics-based biomarker for cytokeratin 19 status of hepatocellular carcinoma with gadoxetic acid-enhanced MRI.
Wang W; Gu D; Wei J; Ding Y; Yang L; Zhu K; Luo R; Rao SX; Tian J; Zeng M
Eur Radiol; 2020 May; 30(5):3004-3014. PubMed ID: 32002645
[TBL] [Abstract][Full Text] [Related]
9. Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses.
Yuen VW; Chiu DK; Law CT; Cheu JW; Chan CY; Wong BP; Goh CC; Zhang MS; Xue HD; Tse AP; Zhang Y; Lau HY; Lee D; Au-Yeung RKH; Wong CM; Wong CC
J Hepatol; 2023 Feb; 78(2):376-389. PubMed ID: 36455783
[TBL] [Abstract][Full Text] [Related]
10. Identification of Novel Tumor Microenvironment-Related Long Noncoding RNAs to Determine the Prognosis and Response to Immunotherapy of Hepatocellular Carcinoma Patients.
Huang S; Zhang J; Lai X; Zhuang L; Wu J
Front Mol Biosci; 2021; 8():781307. PubMed ID: 35004851
[No Abstract] [Full Text] [Related]
11. Chemokine CCL21 determines immunotherapy response in hepatocellular carcinoma by affecting neutrophil polarization.
Xu W; Weng J; Xu M; Zhou Q; Liu S; Hu Z; Ren N; Zhou C; Shen Y
Cancer Immunol Immunother; 2024 Feb; 73(3):56. PubMed ID: 38367070
[TBL] [Abstract][Full Text] [Related]
12. Development of a TMErisk model based on immune infiltration in tumour microenvironment to predict prognosis of immune checkpoint inhibitor treatment in hepatocellular carcinoma.
Yan ZJ; Yu CT; Chen L; Wang HY
Brief Bioinform; 2023 Mar; 24(2):. PubMed ID: 36882021
[TBL] [Abstract][Full Text] [Related]
13. Identification of LOXL3-associating immune infiltration landscape and prognostic value in hepatocellular carcinoma.
Wang N; Zhou X; Tang F; Wang X; Zhu X
Virchows Arch; 2021 Dec; 479(6):1153-1165. PubMed ID: 34448895
[TBL] [Abstract][Full Text] [Related]
14. Hypoxic Characteristic in the Immunosuppressive Microenvironment of Hepatocellular Carcinoma.
Mo Z; Liu D; Rong D; Zhang S
Front Immunol; 2021; 12():611058. PubMed ID: 33679749
[No Abstract] [Full Text] [Related]
15. Radiomics Analysis Based on Multiparametric MRI for Predicting Early Recurrence in Hepatocellular Carcinoma After Partial Hepatectomy.
Zhao Y; Wu J; Zhang Q; Hua Z; Qi W; Wang N; Lin T; Sheng L; Cui D; Liu J; Song Q; Li X; Wu T; Guo Y; Cui J; Liu A
J Magn Reson Imaging; 2021 Apr; 53(4):1066-1079. PubMed ID: 33217114
[TBL] [Abstract][Full Text] [Related]
16. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.
Liu Y; Xun Z; Ma K; Liang S; Li X; Zhou S; Sun L; Liu Y; Du Y; Guo X; Cui T; Zhou H; Wang J; Yin D; Song R; Zhang S; Cai W; Meng F; Guo H; Zhang B; Yang D; Bao R; Hu Q; Wang J; Ye Y; Liu L
J Hepatol; 2023 Apr; 78(4):770-782. PubMed ID: 36708811
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data.
Harkus U; Wankell M; Palamuthusingam P; McFarlane C; Hebbard L
Semin Cancer Biol; 2022 Nov; 86(Pt 3):799-815. PubMed ID: 35065242
[TBL] [Abstract][Full Text] [Related]
18. A radiomics signature associated with underlying gene expression pattern for the prediction of prognosis and treatment response in hepatocellular carcinoma.
Wang D; Zhang L; Sun Z; Jiang H; Zhang J
Eur J Radiol; 2023 Oct; 167():111086. PubMed ID: 37708675
[TBL] [Abstract][Full Text] [Related]
19. Identification of chromatin organization-related gene signature for hepatocellular carcinoma prognosis and predicting immunotherapy response.
Chen J; Chen X; Li T; Wang L; Lin G
Int Immunopharmacol; 2022 Aug; 109():108866. PubMed ID: 35691273
[TBL] [Abstract][Full Text] [Related]
20. Radiomics-based tumor phenotype determination based on medical imaging and tumor microenvironment in a preclinical setting.
Müller J; Leger S; Zwanenburg A; Suckert T; Lühr A; Beyreuther E; von Neubeck C; Krause M; Löck S; Dietrich A; Bütof R
Radiother Oncol; 2022 Apr; 169():96-104. PubMed ID: 35192909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
